Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years

Journal of Pediatrics

Volumn 181, Issue , 2017, Pages 146-153.e3

  Danne, Thomas ^a   Biester, Torben ^a   Kapitzke, Kerstin ^a   Jacobsen, Sanja H ^b   Jacobsen, Lisbeth V ^b   Petri, Kristin C Carlsson ^b   Hale, Paula M ^c   Kordonouri, Olga ^a  

^a Children's Hospital Auf der Bult   (Germany)

^b NOVO NORDISK A S   (Denmark)

^c NOVO NORDISK INC   (United States)

Author keywords

GLP 1 receptor agonist; pharmacodynamics; phase I

Indexed keywords

AMYLASE; ANTIOBESITY AGENT; CALCITONIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LACTATE DEHYDROGENASE; LIRAGLUTIDE; PLACEBO; TRIACYLGLYCEROL LIPASE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADOLESCENT; ADOLESCENT OBESITY; ALOPECIA; AMYLASE BLOOD LEVEL; ARTICLE; BODY MASS; BREAST DISEASE; CALCITONIN BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENITAL SYSTEM DISEASE; GLUCOSE BLOOD LEVEL; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJURY; INSULIN BLOOD LEVEL; INTOXICATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MEDIASTINUM DISEASE; MINIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THORAX DISEASE; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER ABDOMINAL PAIN; VOMITING; AREA UNDER THE CURVE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MAXIMUM TOLERATED DOSE; PATIENT SAFETY; PEDIATRIC OBESITY; REFERENCE VALUE; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; AREA UNDER CURVE; BODY MASS INDEX; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIA; INJECTIONS, SUBCUTANEOUS; LIRAGLUTIDE; MALE; MAXIMUM TOLERATED DOSE; PATIENT SAFETY; PEDIATRIC OBESITY; REFERENCE VALUES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85008227574     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2016.10.076     Document Type: Article

References (26)

1. 1 Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., et al. Global, regional, and national prevalence of overweight and obesity inchildren and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
2. 2 Ogden, C.L., Carroll, M.D., Fryar, C.D., Flegal, K.M., Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS Data Brief, 2015, 1–8.
3. 3 Giannini, C., Caprio, S., Islet function in obese adolescents. Diabetes Obes Metab 14:Suppl 3 (2012), 40–45.
4. 4 Inge, T.H., Courcoulas, A.P., Jenkins, T.M., Michalsky, M.P., Helmrath, M.A., Brandt, M.L., et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 374 (2016), 113–123.
5. 5 Dietz, W.H., Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 101 (1998), 518–525.
6. 6 Wardle, J., Cooke, L., The impact of obesity on psychological well-being. Best Pract Res Clin Endocrinol Metab 19 (2005), 421–440.
7. 7 Simmonds, M., Burch, J., Llewellyn, A., Griffiths, C., Yang, H., Owen, C., et al. The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess 19 (2015), 1–336.
8. 8 Wiegand, S., Keller, K.M., Lob-Corzilius, T., Pott, W., Reinehr, T., Röbl, M., et al. Predicting weight loss and maintenance in overweight/obese pediatric patients. Horm Res Paediatr 82 (2014), 380–387.
9. 9 Barlow, S.E., Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120:Suppl 4 (2007), S164–92.
10. 10 Cole, T.J., Bellizzi, M.C., Flegal, K.M., Dietz, W.H., Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320 (2000), 1240–1243.
11. 11 Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373 (2015), 11–22.
12. 12 Davies, M.J., Bergenstal, R., Bode, B., Kushner, R.F., Lewin, A., Skjøth, T.V., et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314 (2015), 687–699.
13. 13 Petri, K.C., Jacobsen, L.V., Klein, D.J., Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis. Clin Pharmacokinet 54 (2015), 663–670.
14. 14 Lau, D., Davies, M., Pi-Sunyer, X., Wilding, J., Shapiro, L.M., Jensen, C.B., et al. Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double-blind, placebo-controlled 56-week SCALE obesity and prediabetes trial. Endocr Rev, 36(2, Suppl), 2015 Abstract OR07-2.
15. 15 World Health Organization, BMI for age, WHO reference. http://www.who.int/growthref/en/, 2007 Accessed November 21, 2016.
16. 16 Seaquist, E.R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36 (2013), 1384–1395.
17. 17 van Can, J., Sloth, B., Jensen, C.B., Flint, A., Blaak, E.E., Saris, W.H., Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes 38 (2014), 784–793.
18. 18 Wells, J.C., Fewtrell, M.S., Williams, J.E., Haroun, D., Lawson, M.S., Cole, T.J., Body composition in normal weight, overweight and obese children: matched case-control analyses of total and regional tissue masses, and body composition trends in relation to relative weight. Int J Obes (Lond) 30 (2006), 1506–1513.
19. 19 Ingwersen, S.H., Khurana, M., Madabushi, R., Watson, E., Jonker, D.M., Le Thi, T.D., et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol 52 (2012), 1815–1823.
20. 20 Wadden, T.A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P.M., et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 37 (2013), 1443–1451.
21. 21 Blackman, A., Foster, G.D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 40 (2016), 1310–1319.
22. 22 Nuffer, W.A., Trujillo, J.M., Liraglutide: a new option for the treatment of obesity. Pharmacotherapy 35 (2015), 926–934.
23. 23 Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374 (2009), 1606–1616.
24. 24 Klein, D.J., Battelino, T., Chatterjee, D.J., Jacobsen, L.V., Hale, P.M., Arslanian, S., et al. Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther 16 (2014), 679–687.
25. 25 Robinson, L.E., Holt, T.A., Rees, K., Randeva, H.S., O'Hare, J.P., Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open, 3, 2013, e001986.
26. 26 Overgaard, R.V., Petri, K.C., Jacobsen, L.V., Jensen, C.B., Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis. Clin Pharmacokinet 55 (2016), 1413–1422.